AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15126737 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional (blind) transesophageal echocardiography
Number of subjects: 159
Study 15126737 — intervention group
Group type: COMPARATOR
Intervention: Optical transesophageal echocardiography
Number of subjects: 159
Study 11254756 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day for 30 days)
Number of subjects: 6
Study 11254756 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) (600 mg/day for 30 days after a washout period)
Number of subjects: 6
Study 9628403 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased peak movement velocity
Number of subjects: 5
Study 9628403 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of external viscous loads
Number of subjects: 5
Study 8200250 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (400 mg thrice daily for seven days)
Number of subjects: 13
Study 8200250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8200250 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole vs Placebo
Number of subjects: 13
Study 8200250 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 13
Study 3295163 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 141
Study 3295163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 31785838 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted one standard deviation increase of serum 25-hydroxyvitamin D (S-25OHD) concentrations
Number of subjects: 35052
Study 31785838 — intervention group
Group type: COMPARATOR
Intervention: Control group (individuals without ALS)
Number of subjects: 35052
Study 30082180 — intervention group
Group type: EXPERIMENTAL
Intervention: 7° reverse Trendelenburg position (RTP)
Number of subjects: 125
Study 30082180 — intervention group
Group type: COMPARATOR
Intervention: Horizontal position
Number of subjects: 125
Study 28851800 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese version of the Severe Respiratory Insufficiency (SRI) questionnaire
Number of subjects: 149
Study 25798727 — intervention group
Group type: EXPERIMENTAL
Intervention: Positively framed message
Number of subjects: 76
Study 25798727 — intervention group
Group type: EXPERIMENTAL
Intervention: Negatively framed message
Number of subjects: 76
Study 23176776 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with systemic hypertension
Number of subjects: 17
Study 23176776 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 17
Study 20869152 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium liquid-filled soft gelatin capsule (DPSGC) 25 mg
Number of subjects: 249
Study 20869152 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium liquid-filled soft gelatin capsule (DPSGC) 50 mg
Number of subjects: 249
Study 20869152 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium liquid-filled soft gelatin capsule (DPSGC) 100 mg
Number of subjects: 249
Study 20869152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 19594501 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (n = 10)
Number of subjects: 45
Study 19594501 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined verapamil/lithium (Phase 3)
Number of subjects: 45
Study 19594501 — intervention group
Group type: COMPARATOR
Intervention: Continued-lithium (n = 8)
Number of subjects: 45
Study 19594501 — intervention group
Group type: COMPARATOR
Intervention: Lithium monotherapy (Phase 2)
Number of subjects: 45
Study 17285947 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast brachytherapy
Number of subjects: 25
Study 12807406 — intervention group
Group type: EXPERIMENTAL
Intervention: Affiliation goal
Number of subjects: 0
Study 12807406 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsuccessful affiliation attempts
Number of subjects: 0
Study 11374850 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 0
Study 11374850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11374850 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 0
Study 11374850 — intervention group
Group type: COMPARATOR
Intervention: Placebo (AFCAPS/TexCAPS)
Number of subjects: 0
Study 8843920 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-on-yellow perimetry using an argon laser (lambda = 458 nm) with a low background
Number of subjects: 5
Study 8843920 — intervention group
Group type: COMPARATOR
Intervention: Red-on-red perimetry using a HeNe laser (lambda = 633 nm)
Number of subjects: 5
Study 1377484 — intervention group
Group type: EXPERIMENTAL
Intervention: F2 regimen (17 Gy in two fractions of 8.5 Gy 1 week apart)
Number of subjects: 233
Study 1377484 — intervention group
Group type: COMPARATOR
Intervention: F1 regimen (single fraction of 10 Gy)
Number of subjects: 233
Study 1377484 — intervention group
Group type: EXPERIMENTAL
Intervention: F2 regimen
Number of subjects: 233
Study 1377484 — intervention group
Group type: COMPARATOR
Intervention: F1 regimen
Number of subjects: 233
Study 6085377 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (10‐40 mg/day)
Number of subjects: 105
Study 6085377 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine (50‐200 mg/day)
Number of subjects: 105
Study 31427869 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR training with protein (collagen hydrolysate) supplementation
Number of subjects: 30
Study 31427869 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR training with placebo
Number of subjects: 30
Study 31427869 — intervention group
Group type: COMPARATOR
Intervention: Control group without training, but with protein supplementation
Number of subjects: 30
Study 29159774 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline transdermal patch (1.25 mg/24 h, 1.25 mg/48 h, 2.5 mg/48 h, 2.5 mg/72 h)
Number of subjects: 15
Study 29159774 — intervention group
Group type: COMPARATOR
Intervention: Rasagiline oral tablet (1 mg)
Number of subjects: 15
Study 29159774 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline transdermal patch (1.25 mg)
Number of subjects: 15
Study 29159774 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline transdermal patch (2.5 mg)
Number of subjects: 15
Study 29159774 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline transdermal patch (1.25-2.5 mg)
Number of subjects: 15
Study 29159774 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline transdermal patch
Number of subjects: 15
Study 26841365 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplements (800 IU/day)
Number of subjects: 89
Study 26841365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 25138611 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable fixation system (Inion CPS)
Number of subjects: 230
Study 25138611 — intervention group
Group type: COMPARATOR
Intervention: Titanium fixation system (KLS Martin)
Number of subjects: 230
Study 22296077 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD‐alum (four doses)
Number of subjects: 334
Study 22296077 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD‐alum (two doses) followed by placebo (two doses)
Number of subjects: 334
Study 22296077 — intervention group
Group type: COMPARATOR
Intervention: Placebo (four doses)
Number of subjects: 334
Study 22296077 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD‐alum (any dosage)
Number of subjects: 334
Study 22296077 — intervention group
Group type: COMPARATOR
Intervention: Placebo (any dosage)
Number of subjects: 334
Study 20618359 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal exercise test
Number of subjects: 12
Study 20618359 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal exercise test
Number of subjects: 12
Study 20618359 — intervention group
Group type: COMPARATOR
Intervention: Maximal and submaximal exercises
Number of subjects: 12
Study 18240797 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical gel composed of 18% potassium complex, 10% dimethylisosorbide, and 72% aqueous hydroxyethyl cellulose gel applied to the facial skin over painful areas.
Number of subjects: 0
Study 18240797 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical gel application as a first-step procedure before definitive diagnosis and treatment.
Number of subjects: 0
Study 18240797 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical gel application.
Number of subjects: 0
Study 15900603 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib treatment followed by resection of residual disease
Number of subjects: 90
Study 15900603 — intervention group
Group type: COMPARATOR
Intervention: Imatinib treatment
Number of subjects: 90
Study 12463482 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8+ depleted DLI
Number of subjects: 18
Study 12463482 — intervention group
Group type: COMPARATOR
Intervention: Unselected DLI
Number of subjects: 18
Study 12463482 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study 10519615 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (250 mg twice a day) for > or = 5 months
Number of subjects: 32
Study 10519615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 8522669 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat 0.015 mg kg‐1 injected within 5 min to 9 patients
Number of subjects: 18
Study 8522669 — intervention group
Group type: COMPARATOR
Intervention: Control group (9 patients)
Number of subjects: 18
Study 1720527 — intervention group
Group type: EXPERIMENTAL
Intervention: MODE (30 micrograms/kg/min x 15 min, then 7.5 micrograms/kg/min)
Number of subjects: 8
Study 1720527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1720527 — intervention group
Group type: EXPERIMENTAL
Intervention: MODE (at a mean concentration of 774 +/- 229 ng/ml)
Number of subjects: 8
Study 1720527 — intervention group
Group type: EXPERIMENTAL
Intervention: MODE
Number of subjects: 8
Study 6758935 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tiapamil (1 mg/kg loading dose followed by 50 micrograms/kg/min for 2 hours)
Number of subjects: 6
Study 6758935 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tiapamil (approximately 6 mg/kg)
Number of subjects: 6
Study 6758935 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 6
Study 6758935 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 6
Study 30145623 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized intervention (IO and GO)
Number of subjects: 52
Study 30145623 — intervention group
Group type: COMPARATOR
Intervention: Non-optimized intervention (NO)
Number of subjects: 52
Study 29649012 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise program
Number of subjects: 29
Study 29649012 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic exercise program
Number of subjects: 29
Study 27396815 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed sports therapy (PST)
Number of subjects: 64
Study 24743431 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibric acid (FA) 135 mg plus atorvastatin
Number of subjects: 0
Study 24743431 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin monotherapy
Number of subjects: 0
Study 24743431 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibric acid (FA) plus atorvastatin
Number of subjects: 0
Study 22052941 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) 1.5 mg
Number of subjects: 7
Study 22052941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 19345869 — intervention group
Group type: EXPERIMENTAL
Intervention: FasT-Fix suture devices
Number of subjects: 10
Study 19345869 — intervention group
Group type: COMPARATOR
Intervention: 2-0 polydioxane (PDS) sutures
Number of subjects: 10
Study 17244773 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg
Number of subjects: 0
Study 17244773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15151330 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Simply‐White Whitening Gel (5.9% hydrogen peroxide)
Number of subjects: 30
Study 15151330 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 30
Study 11703565 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue/green LED
Number of subjects: 66
Study 11703565 — intervention group
Group type: EXPERIMENTAL
Intervention: Light box
Number of subjects: 66
Study 11703565 — intervention group
Group type: EXPERIMENTAL
Intervention: White LED
Number of subjects: 66
Study 11703565 — intervention group
Group type: COMPARATOR
Intervention: No light control group
Number of subjects: 66
Study 10987677 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone substitution (2 IU/m2) for 12 months
Number of subjects: 25
Study 7992358 — intervention group
Group type: EXPERIMENTAL
Intervention: Towne strain attenuated CMV vaccine
Number of subjects: 0
Study 7992358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2572266 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 0
Study 49737 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga relaxation methods with bio-feedback
Number of subjects: 34
Study 49737 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy (general relaxation)
Number of subjects: 34
Study 49737 — intervention group
Group type: COMPARATOR
Intervention: Yoga relaxation methods with bio-feedback (after control group trained)
Number of subjects: 34
Study 31171074 — intervention group
Group type: COMPARATOR
Intervention: Pulpectomy
Number of subjects: 830
Study 31171074 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric sulfate (FS) pulpotomy
Number of subjects: 830
Study 31171074 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite (SH) pulpotomy
Number of subjects: 830
Study 27481122 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional interventions
Number of subjects: 123
Study 27481122 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 123
Study 27481122 — intervention group
Group type: EXPERIMENTAL
Intervention: Both nutritional interventions and physical exercise
Number of subjects: 123
Study 27481122 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological outcome variables
Number of subjects: 123
Study 27481122 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle mass, muscle strength, and physical performance
Number of subjects: 123
Study 26342653 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent dyssynchrony after CRT-D
Number of subjects: 151
Study 26342653 — intervention group
Group type: EXPERIMENTAL
Intervention: New dyssynchrony after CRT-D
Number of subjects: 151
Study 23760914 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐micron continuous‐wave laser resection (2‐µm laser)
Number of subjects: 120
Study 23760914 — intervention group
Group type: COMPARATOR
Intervention: Conventional monopolar transurethral resection of bladder tumour (TURBT)
Number of subjects: 120
Study 22093054 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) filler
Number of subjects: 12
Study 22093054 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA) filler with nonablative infrared (IR) device
Number of subjects: 12
Study 17586581 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg)
Number of subjects: 12
Study 17586581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16437283 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparotomy cholecystectomy (MC)
Number of subjects: 157
Study 16437283 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 157
Study 12766641 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (1 mg intravenous)
Number of subjects: 20
Study 12766641 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine infusion
Number of subjects: 20
Study 11287028 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE+MPA regimens
Number of subjects: 60
Study 11287028 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 60
Study 11287028 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE+MPA and Tibolone
Number of subjects: 60
Study 11287028 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE+MPA, Tibolone
Number of subjects: 60
Study 11287028 — intervention group
Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 60
Study 9291200 — intervention group
Group type: COMPARATOR
Intervention: Usual-protein diet (1.3 g/kg/day)
Number of subjects: 840
Study 9291200 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.58 g/kg/day)
Number of subjects: 840
Study 9291200 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-protein diet (0.28 g/kg/day) supplemented with a ketoacid-amino acid mixture (0.28 g/kg/day)
Number of subjects: 840
Study 9291200 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein and very-low-protein diets combined
Number of subjects: 840
Study 8340295 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation for 36 hours
Number of subjects: 17
Study 3543705 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral colistin
Number of subjects: 145
Study 3543705 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 145
Study 3543705 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephradine
Number of subjects: 145
Study 3543705 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 145
Study 3543705 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic use of antibiotics
Number of subjects: 145
Study 30968632 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus rhamnosus GG)
Number of subjects: 150
Study 30968632 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 150
Study 27838144 — intervention group
Group type: EXPERIMENTAL
Intervention: In-Home Cognitive Behavioral Therapy (IH-CBT)
Number of subjects: 0
Study 27838144 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 0
Study 26264735 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based CBT with protocol driven feedback
Number of subjects: 240
Study 26264735 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based CBT with support on demand
Number of subjects: 240
Study 26264735 — intervention group
Group type: COMPARATOR
Intervention: Wait list
Number of subjects: 240
Study 26264735 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based CBT formats
Number of subjects: 240
Study 26264735 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based CBT interventions
Number of subjects: 240
Study 22858150 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 16
Study 22858150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 21122063 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) of pioglitazone 15mg/metformin 850mg twice daily (bid)
Number of subjects: 0
Study 21122063 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15mg bid
Number of subjects: 0
Study 21122063 — intervention group
Group type: COMPARATOR
Intervention: Metformin 850mg bid
Number of subjects: 0
Study 21122063 — intervention group
Group type: EXPERIMENTAL
Intervention: All three treatments
Number of subjects: 0
Study 21122063 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC and pioglitazone
Number of subjects: 0
Study 21122063 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC
Number of subjects: 0
Study 18209255 — intervention group
Group type: EXPERIMENTAL
Intervention: Class-based exercise program (CB)
Number of subjects: 172
Study 18209255 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise program (HB)
Number of subjects: 172
Study 18209255 — intervention group
Group type: COMPARATOR
Intervention: Control group (HB)
Number of subjects: 172
Study 17205827 — intervention group
Group type: EXPERIMENTAL
Intervention: Huangbai Liquid (HL)
Number of subjects: 27
Study 17205827 — intervention group
Group type: COMPARATOR
Intervention: famciclovir
Number of subjects: 27
Study 15301640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral treatment (CBT)
Number of subjects: 549
Study 15301640 — intervention group
Group type: COMPARATOR
Intervention: Health education (HE)
Number of subjects: 549
Study 10886123 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol
Number of subjects: 8
Study 10886123 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxy‐progesterone
Number of subjects: 8
Study 10886123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9052519 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-aminosalicylic acid (4-ASA) 6 g per day for 6 weeks
Number of subjects: 30
Study 9052519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9052519 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-ASA
Number of subjects: 30
Study 8419226 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E2) transdermally
Number of subjects: 57
Study 8419226 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 57
Study 3948539 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 59
Study 3948539 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin plus netilmicin
Number of subjects: 59
Study 30840567 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 0
Study 27845482 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group using games (cards and board games) and physical activities
Number of subjects: 0
Study 27845482 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 24231655 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergame training (24 1-hr sessions)
Number of subjects: 24
Study 24231655 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 22286156 — intervention group
Group type: EXPERIMENTAL
Intervention: RV apical (RV‐A)
Number of subjects: 85
Study 22286156 — intervention group
Group type: COMPARATOR
Intervention: RV high posterior septal (RV‐HS)
Number of subjects: 85